Susan H Tam
Overview
Explore the profile of Susan H Tam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho M, Tam S, Shi L, Fung I, Tornetta M, Canziani G, et al.
Clin Exp Immunol
. 2025 Feb;
PMID: 39964852
Interleukin-1β (IL-1β) is a key mediator of innate immunity against pathogen infections. However, dysregulated IL-1β activity is associated with various autoinflammatory, autoimmune, degenerative, atherosclerotic diseases, and cancers. Biologic drugs that...
2.
Shi L, Yu M, Jin Y, Chen P, Mu G, Tam S, et al.
Front Immunol
. 2024 Dec;
15:1442588.
PMID: 39726595
Introduction: Thymic stromal lymphopoietin (TSLP) is a master regulator of allergic inflammation against pathogens at barrier surfaces of the lung, skin, and gut. However, aberrant TSLP activity is implicated in...
3.
Tam S, McCarthy S, Armstrong A, Somani S, Wu S, Liu X, et al.
Antibodies (Basel)
. 2019 Sep;
6(3).
PMID: 31548527
Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG) antibodies to eliminate their immune effector functions while retaining other Fc characteristics has numerous applications, including blocking antigens on Fc...
4.
Goulet D, Watson M, Tam S, Zwolak A, Chiu M, Atkins W, et al.
Drug Metab Dispos
. 2018 Sep;
46(12):1900-1907.
PMID: 30232177
The serum half-life and clearance of therapeutic monoclonal antibodies (mAbs) are critical factors that impact their efficacy and optimal dosing regimen. The pH-dependent binding of an mAb to the neonatal...
5.
Zwolak A, Leettola C, Tam S, Goulet D, Derebe M, Pardinas J, et al.
Sci Rep
. 2017 Nov;
7(1):15521.
PMID: 29138497
Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives are critical for therapeutic programs. Here, we identify 3 mutations (T307P, L309Q, and Q311R or "TLQ") in the...
6.
Zwolak A, Armstrong A, Tam S, Pardinas J, Goulet D, Zheng S, et al.
MAbs
. 2017 Sep;
9(8):1306-1316.
PMID: 28898162
The increased number of bispecific antibodies (BsAb) under therapeutic development has resulted in a need for mouse surrogate BsAbs. Here, we describe a one-step method for generating highly pure mouse...
7.
Zhang D, Armstrong A, Tam S, McCarthy S, Luo J, Gilliland G, et al.
MAbs
. 2017 Aug;
9(7):1129-1142.
PMID: 28758875
Immunostimulatory receptors belonging to the tumor necrosis factor receptor (TNFR) superfamily are emerging as promising targets for cancer immunotherapies. To optimize the agonism of therapeutic antibodies to these receptors, Fc...
8.
Nnane I, Han C, Jiao Q, Tam S, Davis H, Xu Z
Basic Clin Pharmacol Toxicol
. 2017 Jan;
121(1):13-21.
PMID: 28132416
The purpose of this study was to evaluate the pharmacokinetics (PK) of anti-oncostatin M (OSM) IgG1 monoclonal antibodies, CNTO 1119 and its Fc variant (CNTO 8212), which incorporates the LS(Xtend)...
9.
Hornby P, Cooper P, Kliwinski C, Ragwan E, Mabus J, Harman B, et al.
Pharm Res
. 2013 Sep;
31(4):908-22.
PMID: 24072267
Purpose: To evaluate transcytosis of immunoglobulin G (IgG) by the neonatal Fc receptor (FcRn) in adult primate intestine to determine whether this is a means for oral delivery of monoclonal...
10.
Tam S, McCarthy S, Brosnan K, Goldberg K, Scallon B
MAbs
. 2013 Apr;
5(3):397-405.
PMID: 23549129
Transgenic mice expressing human neonatal Fc receptor (FcRn) instead of mouse FcRn are available for IgG antibody pharmacokinetic (PK) studies. Given the interest in a rodent model that offers reliable...